false
OasisLMS
Login
Catalog
Kidney Week 2026 Early Program On-Demand - Glomeru ...
Renal Amyloidosis: Updates in Typing, Classificati ...
Renal Amyloidosis: Updates in Typing, Classification, and Treatment Recommendations
Back to course
[Please upgrade your browser to play this video content]
Video Transcription
Video Summary
Dr. Nelson Leung reviewed the diagnosis and management of renal amyloidosis, emphasizing that more than 40 amyloid types exist and treatments are type-specific. Accurate typing is therefore essential. Kidney biopsy with Congo red confirms amyloid, while laser microdissection followed by mass spectrometry is the preferred method for identifying the amyloid protein; immunofluorescence can misclassify cases.<br /><br />AL amyloidosis commonly affects both kidneys and heart. Management includes careful fluid control and attention to orthostatic hypotension. Renal outcomes are linked to proteinuria, kidney function, and hematologic response. Daratumumab-based therapy has substantially improved outcomes, with newer immune therapies also showing promise.<br /><br />AA amyloidosis is generally driven by chronic inflammation, so treatment targets the underlying infection, autoimmune disease, or inflammatory syndrome. The talk also covered hereditary forms, including fibrinogen, apolipoprotein, and transthyretin amyloidosis, for which transplant decisions and emerging therapies depend on the specific type. Iatrogenic amyloid can arise from injected peptide drugs. ALECT2 is a significant cause of renal amyloidosis, particularly in some ethnic groups, but currently has no specific treatment.<br /><br />The discussion reinforced that amyloid typing can guide therapy, predict kidney-transplant outcomes, and identify risks to other organs.
Asset Caption
Nelson Leung, MD
Meta Tag
Speaker
Nelson Leung
Keywords
renal amyloidosis
amyloid typing
kidney biopsy
mass spectrometry
AL amyloidosis
AA amyloidosis
daratumumab
×
Please select your language
1
English